Diagnostic yield of chromosomal microarray in the largest Latino clinical cohort

• Published in: American journal of medical genetics. Part A 2024-02, Vol.194 (2), p.218-225
• Main Authors: Carrillo, Yina D., Rueda‐Gaitán, Paula, Gualdrón, Orlando, Estrada‐Serrato, Carlos, Castro‐Cuesta, Taryn A., Londoño, Olga, Rodríguez‐Salazar, Luna, Isaza‐Ruget, Mario, Arcos‐Burgos, Mauricio, López Rivera, Juan Javier
• Format: Article
• Language: English
• Subjects: chromosomal microarray analysis; Chromosome Aberrations; Chromosomes; Chromosomes, Human, Pair 15; CNV; Colombian patients; Congenital defects; Copy number; copy number variant; DNA Copy Number Variations - genetics; Epilepsy; Genetic disorders; Humans; Microarray Analysis; molecular diagnosis; neurodevelopmental delay; Patients; Phenotypes
• ISSN: 1552-4825; 1552-4833; 1552-4833
• DOI: 10.1002/ajmg.a.63427

Copy number variants (CNVs) remain a major etiological cause of neurodevelopmental delay and congenital malformations. Chromosomal microarray analysis (CMA) represents the gold standard for CNVs molecular characterization. We applied CMA throughout the patient's clinical diagnostic workup, as the patient's medical provider requested. We collected CMA results of 3380 patients enrolled for 5 years (2016–2021). We found 830 CNVs in 719 patients with potential clinical significance, that is, (i) pathogenic, (ii) likely pathogenic, and (iii) variants of uncertain significance (VUS), from which 10.6% (predominantly involving chromosomes 15 and 22) were most likely the final cause underpinning the patients' clinical phenotype. For those associated with neurodevelopmental phenotypes, the rate of pathogenic or likely pathogenic findings among the patients with CNVs was 60.75%. When considering epileptic phenotypes, it was 59%. Interestingly, our protocol identified two gains harbored in 17q21.31 and 9q34.3, internationally classified initially as VUS. However, because of their high frequency, we propose that these two VUS be reclassified as likely benign in this widely heterogeneous phenotypic population. These results support the diagnostic yield efficiency of CMA in characterizing CNVs to define the final molecular cause of genetic diseases in this cohort of Colombian patients, the most significant sample of patients from a Latino population, and define new benign polymorphic CNVs.